Dermtech Profile

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:4em;padding-top: 15px;;'>DE</div>

Performance

11 / 100

Odds of Distress

Analyze Filter   Check how we calculate scores
Equity ratings for Dermtech are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting October 30, 2019 and ending today January 28, 2020. Please note, there could be an existing legal relationship between Dermtech (DMTK) and Constellation Alpha (CNACU). Click here to learn more.

Dermtech Profile

DermTech, Inc., a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California. Dermtech operates under Diagnostics Research classification in USA and is traded on BATS Exchange. It employs 36 people. more on Dermtech
Dermtech Fama & French Healthcare
Healthcare
Fama & French Classification
Dermtech SEC Filings
Dermtech SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameDermtech
Related EntityCNACU (Constellation Alpha Capital Corp Unit)
Thematic Classification
Currently Active Investing Idea
  Healthcare
View All
Average Analyst Recommendation
Piotroski F Score
Academic score to determine the current strength of Dermtech financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Financial Strength
Dermtech ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt to Equity Ratio
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Profitability
Few selected profitability drivers of Dermtech representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Dermtech (DMTK) is traded on BATS Exchange in USA. It is located in 11099 North Torrey Pines Road and employs 36 people. Dermtech is listed under Healthcare category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 69.15 M. Dermtech conducts business under Healthcare sector and is part of Diagnostics & Research industry. The entity has 2.67 M outstanding shares of which 120.63 K shares are currently shorted by private and institutional investors with about 1.38 trading days to cover. The company currently holds about 2.12 M in cash with (8.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18.
Check Dermtech Probability Of Bankruptcy

Ownership Allocation (%)

Dermtech Target Price Odds Analysis

Odds Below 14.38HorizonTargetOdds Above 14.38
96.80%30 days 14.38 3.18%
Based on normal probability distribution, the odds of Dermtech to move above current price in 30 days from now is under 4 (This Dermtech probability density function shows the probability of Dermtech Stock to fall within a particular range of prices over 30 days) .

Dermtech Top Holders

Dermtech Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Rtw Investments LpCommon Shares2.4 M12.5 M
Farallon Capital Management LlcCommon Shares615.4 K3.4 M
Boothbay Fund Management LlcWarrants274 K1.5 M
View Dermtech Diagnostics

Dermtech Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Dermtech Against Markets

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Dermtech Corporate Filings

Dermtech SEC Reporting

Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Other Events
Unclassified Corporate Event. Unclassified Corporate Event
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Continue to Investing Opportunities. Please also try Portfolio Reporting module to create custom reports across your portfolios and generate quick suggestion pitch.
Company logos by clearbit